Skip to main content
. 2012 Jul 6;1:21. doi: 10.4103/2277-9175.98122

Figure 1.

Figure 1

The VH and V-KAPPA domains of the Trastuzumab, Pertuzumab, Dual specific bH1, Bevacizumab, and Cetuximab